IVX Health is a national provider of outpatient infusion and injection therapy for patients with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis. Its experience-first model emphasizes patient amenities including guaranteed private suites, flat-screen TVs with streaming, high-speed Wi‑Fi, leather recliners with seating for guests, and flexible evening and weekend scheduling. Operating over 50 infusion centers across 16 markets, IVX says it achieved record milestones for opening new centers, caring for new patients, and entering new states in the past year. The company reports an industry-leading 97 Net Promoter Score and was named to Modern Healthcare’s Best Places to Work list for a third consecutive year. IVX positions itself as a cost-effective, convenient alternative to hospital-based infusion care and aims to become the nation’s preferred destination of pharmaceutical care. It plans to use new capital to accelerate entry into additional markets and to collaborate with other providers in the healthcare ecosystem. IVX Health (doing business as Infusion Express) is a patient-focused operator of ambulatory infusion centers that provides infusion and injection therapy for patients with complex chronic conditions. Led by CEO Doug Ghertner and based in Nashville, the company treats conditions such as rheumatoid arthritis, Crohn’s disease and multiple sclerosis. Its centers are located in the communities where patients live and offer flexible scheduling including evenings and weekends, private suites with high-speed Wi‑Fi, flat-screen TVs and comfortable recliners with room for guests. The company operates under the Infusion Express brand in Kansas City, Philadelphia, Chicago and San Francisco, and plans near-term openings in Nashville, Harrisburg and Columbus. IVX Health said it will further expand into additional markets in 2020. In May 2019 it completed a $22.5M funding round to accelerate expansion of its physical footprint and enter new markets across the country.

Total raised

$123M

Funding rounds

2

Latest round

Series F

Latest activity

Sep 2021